ACAD - ACADIA Pharma Debt to Book Capitalization Ratio

ACADIA Pharmaceuticals (ACAD) maintains an impeccable reputation in the therapy of severe brain pathologies. This chart of the asset's value on the GURU.Markets platform is currently at 0.06. The company leverages its monopoly position in treating rare genetic disorders, where a total lack of alternatives guarantees absolute patient loyalty. US-based drug manufacturing capacities ensure business stability within narrow market segments.

For ACADIA Pharmaceuticals (ACAD), which is vulnerable to raw material supply disruptions and global testing, the debt-to-equity ratio serves as an indicator of financial flexibility. This metric is calculated as the ratio of total liabilities to total equity, demonstrating the business's degree of dependence on creditors and determining the balance between profitability growth and insolvency risk.